<DOC>
	<DOCNO>NCT00180830</DOCNO>
	<brief_summary>The purpose study determine whether Glivec effective , child , adolescent young adult , treatment malignant disease evidence suggest potential pathogenic role one tyrosine kinases know inhibited Glivec .</brief_summary>
	<brief_title>Glivec Phase II Pediatric Study</brief_title>
	<detailed_description />
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Patients 6 month 21 year age . Malignant disease document conventional criterion refractory standard , approve therapy , conventional therapy definitive benefit exist . Immunohistochemistry documentation positivity either Kit ( CD117 ) PDGFR tumor tissue relevant . Each positive tumor centrally review inclusion patient trial . Measurable evaluable disease . WHO Performance status 0,1 , 2 Lansky Play Scale &gt; = 50 % . Adequate organ function , define follow : total bilirubin &lt; 1.5 x ULN , SGOT SGPT &lt; 2.5 x UNL ( &lt; 5 x ULN hepatic disease involvement present ) , creatinine &lt; 1.5 x ULN , ANC &gt; 1x 109/L , platelet &gt; 75 x 109/L . Female patient childbearing potential must negative pregnancy test within 7 day initiation study drug dosing . Male female patient reproductive potential must agree employ effective barrier method birth control throughout study 3 month follow discontinuation study drug . Life expectancy 6 week . Written , voluntary , informed consent , include consent retrieval investigational use tissue sample evaluation sign parent young adult patient . National , need , local ethical approval . Patient hematological disease positive chimeric BCRABL fusion protein ckit . Patient receive investigational agent within 28 day first day study drug dose . Female patient pregnant breastfeeding . Patient another severe and/or lifethreatening medical diseasePatient acute know chronic liver disease ( e.g. , chronic active hepatitis , cirrhosis ) . Patient known diagnosis human immunodeficiency virus ( HIV ) infection . Patient receive chemotherapy within 4 week ( 6 week nitrosourea , mitomycinC antibody therapy ) prior study entry unless urgent enrollment need approve study coordinator .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>September 2006</verification_date>
</DOC>